Cure My Disease

Don't miss your cure!

 Log in / Sign up

A common diabetes drug may protect against hormone therapy's metabolic side effects

NCT ID NCT03031821

Terminated Disease control Sponsor: Canadian Urologic Oncology Group Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether metformin, a standard diabetes medication, can prevent or reverse metabolic syndrome in men with prostate cancer who are starting androgen deprivation therapy (ADT). Metabolic syndrome—a cluster of conditions like high blood sugar, high blood pressure, and excess belly fat—is a common side effect of ADT. The study randomly assigns 166 participants to receive either metformin or a placebo for 18 months, and measures how many develop metabolic syndrome by the end of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
metformin
What this could lead to
If it works, metformin could become a simple way to reduce metabolic side effects from hormone therapy in prostate cancer patients.
What could go wrong
This is a mid-stage trial with 166 participants, so results may not apply to all patients. Metformin can cause gastrointestinal side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome metabolic syndrome X prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METABOLIC SYNDROME PROSTATE CANCER

Contacts and locations

Locations

  • BC Cancer Agency - Vancouver Cancer Centre

    Vancouver, British Columbia, V5Z 4E6, Canada

  • CHU de Quebec - Universite Laval

    Laval, Quebec, Canada

  • Cancer Care Manitoba

    Winnepeg, Manitoba, R3E 0V9, Canada

  • Central Newfoundland Regional Health Centre

    Grand Falls-Windsor, Newfoundland and Labrador, A2A 2E1, Canada

  • Centre Hospitalier de L'Universite de Montreal (CHUM)

    Montreal, Quebec, H2X 0A9, Canada

  • Centre Intégré Universitaire de Santé et de Services Sociaux de la Mauricie-Centre-du-Québec / Centre hospitalier régional

    Trois-Rivières, Quebec, G8Z 3R9, Canada

  • Ciusss-Chus

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, T6G 1Z2, Canada

  • Dr. H. Bliss Murphy Cancer Centre

    St. John's, Newfoundland and Labrador, A1B 8V6, Canada

  • Horizon Health Network

    Saint John, New Brunswick, E3B 4R3, Canada

  • McGill University Health Center-Cedar Cancer Center

    Montreal, Quebec, H4A 3J1, Canada

  • Northeast Cancer Centre

    Greater Sudbury, Ontario, P3E 5J1, Canada

  • Princess Margaret Cancer Centre (Princess Margaret Hospital)

    Toronto, Ontario, M5G 2M9, Canada

  • Sunnybrook Research Institue

    Toronto, Ontario, M4N 3M5, Canada

  • Tom Baker Cancer Centre

    Calgary, Alberta, T2S 3C3, Canada

  • Vancouver Prostate Centre

    Vancouver, British Columbia, V5Z 1M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.